Giuseppe
Emeritus
Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury (CHEST, abstract, edited)
[Source: Chest, full text: <cite cite="http://chestjournal.chestpubs.org/content/138/4/965.short?rss=1">Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury ? CHEST</cite>. Abstract, edited.]
Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury
1. Michael A. Matthay, MD, 2. B. Taylor Thompson, MD, 3. Elizabeth J. Read, MD, 4. David H. McKenna Jr, MD, 5. Kathleen D. Liu, MD, PhD, 6. Carolyn S. Calfee, MD and 7. Jae Woo Lee, MD
Author Affiliations
1. From the Departments of Medicine, Anesthesiology, and The Cardiovascular Research Institute at the University of California (Drs Matthay, Liu, Calfee, and Lee), San Francisco, CA; Blood Systems Research Institute (Dr Read), San Francisco, CA; Molecular and Cellular Therapeutics (Dr McKenna), University of Minnesota, Saint Paul, MN; and the Massachusetts General Hospital (Dr Thompson), Harvard Medical School, Boston, MA.
1. Correspondence to: Michael A. Matthay, MD, Departments of Medicine and Anesthesiology, 505 Parnassus Ave, M-917, San Francisco, CA 94143-0624; e-mail: michael.matthay@ucsf.edu
Abstract
Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a brief review of the biologic qualities of MSC that make them suitable for the treatment of human diseases, as well as the experimental data that provide support for their potential efficacy for critically ill patients with acute respiratory failure from ALI. The article then discusses which patients with ALI might be the best candidates for cell-based therapy and provides a template for the regulatory and practical steps that will be required to test allogeneic human MSC in patients with severe ALI. There is a dual focus on how to design trials for testing both safety and efficacy.
Footnotes
* Funding/support: This study was supported by the National Heart, Blood, and Lung Institute (NHBLI) [NHBLI Grants R37 HL51856 and R01 HL51854] (Dr Matthay); [NHBLI Grant HL093026] (Dr Lee); [NHBLI Grants HL090833 and FAMRI] (Dr Calfee); [NHBLI Grant R37HL51856] (Dr Thompson); and [NHBLI Grant N01HB37164] (Dr McKenna).
* Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
#Abbreviations
ALI acute lung injury
IL interleukin
KGF keratinocyte growth factor
MSC mesenchymal stem cells
NHBLI National Heart, Blood, and Lung Institute
PGE2 prostaglandin E2
* Received February 23, 2010.
* Accepted May 28, 2010.
* ? 2010 American College of Chest Physicians
-
------<cite cite="http://chestjournal.chestpubs.org/content/138/4/965.short?rss=1"></cite>
[Source: Chest, full text: <cite cite="http://chestjournal.chestpubs.org/content/138/4/965.short?rss=1">Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury ? CHEST</cite>. Abstract, edited.]
Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury
1. Michael A. Matthay, MD, 2. B. Taylor Thompson, MD, 3. Elizabeth J. Read, MD, 4. David H. McKenna Jr, MD, 5. Kathleen D. Liu, MD, PhD, 6. Carolyn S. Calfee, MD and 7. Jae Woo Lee, MD
Author Affiliations
1. From the Departments of Medicine, Anesthesiology, and The Cardiovascular Research Institute at the University of California (Drs Matthay, Liu, Calfee, and Lee), San Francisco, CA; Blood Systems Research Institute (Dr Read), San Francisco, CA; Molecular and Cellular Therapeutics (Dr McKenna), University of Minnesota, Saint Paul, MN; and the Massachusetts General Hospital (Dr Thompson), Harvard Medical School, Boston, MA.
1. Correspondence to: Michael A. Matthay, MD, Departments of Medicine and Anesthesiology, 505 Parnassus Ave, M-917, San Francisco, CA 94143-0624; e-mail: michael.matthay@ucsf.edu
Abstract
Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a brief review of the biologic qualities of MSC that make them suitable for the treatment of human diseases, as well as the experimental data that provide support for their potential efficacy for critically ill patients with acute respiratory failure from ALI. The article then discusses which patients with ALI might be the best candidates for cell-based therapy and provides a template for the regulatory and practical steps that will be required to test allogeneic human MSC in patients with severe ALI. There is a dual focus on how to design trials for testing both safety and efficacy.
Footnotes
* Funding/support: This study was supported by the National Heart, Blood, and Lung Institute (NHBLI) [NHBLI Grants R37 HL51856 and R01 HL51854] (Dr Matthay); [NHBLI Grant HL093026] (Dr Lee); [NHBLI Grants HL090833 and FAMRI] (Dr Calfee); [NHBLI Grant R37HL51856] (Dr Thompson); and [NHBLI Grant N01HB37164] (Dr McKenna).
* Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
#Abbreviations
ALI acute lung injury
IL interleukin
KGF keratinocyte growth factor
MSC mesenchymal stem cells
NHBLI National Heart, Blood, and Lung Institute
PGE2 prostaglandin E2
* Received February 23, 2010.
* Accepted May 28, 2010.
* ? 2010 American College of Chest Physicians
-
------<cite cite="http://chestjournal.chestpubs.org/content/138/4/965.short?rss=1"></cite>